From: Claudin-low breast cancers: clinical, pathological, molecular and prognostic characterization
A. Clinicopathological features | Claudin-low | All samples | ||||||||
---|---|---|---|---|---|---|---|---|---|---|
N | RD | pCR | p-value* | OR [95CI] | N | RD | pCR | p-value* | OR [95CI] | |
Age at diagnosis, years | Â | Â | Â | 0.392 | 0.76 | Â | Â | Â | 0.09 | 0.8 |
≤50 | 123 | 80 (52%) | 43 (59%) |  | [0.41-1.37] | 697 | 521 (53%) | 176 (58%) |  | [0.61-1.04] |
>50 | 104 | 74 (48%) | 30 (41%) | Â | Â | 595 | 469 (47%) | 126 (42%) | Â | Â |
Pathological tumor size | Â | Â | Â | 1.00 | 0.93 | Â | Â | Â | 0.859 | 1.1 |
pT1 | 5 | 3 (8%) | 2 (9%) | Â | [0.1-11.96] | 44 | 32 (14%) | 12 (13%) | Â | [0.53-2.53] |
pT2-3 | 55 | 34 (92%) | 21 (91%) | Â | Â | 279 | 196 (86%) | 83 (87%) | Â | Â |
Histological grade | Â | Â | Â | 0.06 | Inf | Â | Â | Â | 1.68E-04 | 8.1 |
1 | 8 | 8 (6%) | 0 (0%) | Â | [0.82-Inf] | 53 | 51 (6%) | 2 (1%) | Â | [2.11-69.38] |
2-3 | 204 | 136 (94%) | 68 (100%) | Â | Â | 1126 | 854 (94%) | 272 (99%) | Â | Â |
Histological type | Â | Â | Â | 0.125 | Â | Â | Â | Â | 0.75 | Â |
IDC | 77 | 45 (67%) | 32 (84%) | Â | Â | 468 | 337 (82%) | 131 (85%) | Â | Â |
ILC | 5 | 3 (4%) | 2 (5%) | Â | Â | 15 | 10 (2%) | 5 (3%) | Â | Â |
MIX | 6 | 6 (9%) | 0 (0%) | Â | Â | 37 | 29 (7%) | 8 (5%) | Â | Â |
other | 17 | 13 (19%) | 4 (11%) | Â | Â | 47 | 36 (9%) | 11 (7%) | Â | Â |
ESR1 expression status | Â | Â | Â | 0.07 | 0.47 | Â | Â | Â | 7.21E-18 | 0.3 |
negative | 183 | 119 (77%) | 64 (88%) | Â | [0.19-1.07] | 697 | 470 (47%) | 227 (75%) | Â | [0.22-0.4] |
positive | 45 | 36 (23%) | 9 (12%) | Â | Â | 597 | 522 (53%) | 75 (25%) | Â | Â |
PGR expression status | Â | Â | Â | 0.42 | 0.64 | Â | Â | Â | 4.24E-08 | 0.38 |
negative | 195 | 130 (84%) | 65 (89%) | Â | [0.24-1.57] | 979 | 716 (72%) | 263 (87%) | Â | [0.26-0.56] |
positive | 33 | 25 (16%) | 8 (11%) | Â | Â | 315 | 276 (28%) | 39 (13%) | Â | Â |
ERBB2 expression status | Â | Â | Â | 0.472 | 1.7 | Â | Â | Â | 5.90E-04 | 1.9 |
negative | 219 | 150 (97%) | 69 (95%) | Â | [0.33-8.34] | 1125 | 881 (89%) | 244 (81%) | Â | [1.31-2.7] |
positive | 9 | 5 (3%) | 4 (5%) | Â | Â | 169 | 111 (11%) | 58 (19%) | Â | Â |
Triple-negative expression status | Â | Â | Â | 0.285 | 1.4 | Â | Â | Â | 8.16E-10 | 2.3 |
no | 71 | 52 (34%) | 19 (26%) | Â | [0.74-2.83] | 777 | 642 (65%) | 135 (45%) | Â | [1.73-2.97] |
yes | 157 | 103 (66%) | 54 (74%) | Â | Â | 517 | 350 (35%) | 167 (55%) | Â | Â |
DLDA30 [18] | Â | Â | Â | 1.61E-02 | 0.49 | Â | Â | Â | 7.53E-23 | 0.26 |
pCR-like | 120 | 73 (47%) | 47 (64%) | Â | [0.27-0.91] | 439 | 264 (27%) | 175 (58%) | Â | [0.2-0.35] |
RD-like | 108 | 82 (53%) | 26 (36%) | Â | Â | 855 | 728 (73%) | 127 (42%) | Â | Â |
Stromal metagene [51] | Â | Â | Â | 0.623 | 1.2 | Â | Â | Â | 0.12 | 0.81 |
pCR-like | 55 | 39 (25%) | 16 (22%) | Â | [0.59-2.5] | 642 | 480 (48%) | 162 (54%) | Â | [0.62-1.06] |
RD-like | 173 | 116 (75%) | 57 (78%) | Â | Â | 652 | 512 (52%) | 140 (46%) | Â | Â |
A-score [21] | Â | Â | Â | 3.15E-03 | 3.9 | Â | Â | Â | 1.48E-04 | 2 |
RD-like | 37 | 31 (32%) | 6 (11%) | Â | [1.46-12.32] | 258 | 196 (46%) | 62 (30%) | Â | [1.36-2.85] |
pCR_Like | 118 | 67 (68%) | 51 (89%) | Â | Â | 378 | 233 (54%) | 145 (70%) | Â | Â |
RB-loss signature [52] | Â | Â | Â | 1.00 | 0.96 | Â | Â | Â | 6.52-03 | 1.7 |
Low (RD-like) | 212 | 144 (93%) | 68 (93%) | Â | [0.25-3.15] | 1150 | 895 (90%) | 255 (84%) | Â | [1.14-2.51] |
High (pCR-like) | 16 | 11 (7%) | 5 (7%) | Â | Â | 144 | 97 (10%) | 47 (16%) | Â | Â |